Clickotine in AI answers

Click Therapeutics develops personalized, data-driven digital therapeutics for chronic health conditions using its CLICK Neurobehavioral Intervention Platform. Its digital program Clickotine targets smoking cessation and, in an 8-week fully remote trial with 416 participants, showed high engagement and that 45.2% stopped smoking for at least 7 days while 26.2% achieved 30‑day abstinence, with engagement tied to higher quit rates. The company plans larger randomized trials, broader applications to other addictions and chronic conditions, and partnerships to offer a commercial version with live coaching and nicotine replacement therapy (NRT).